{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:43:41Z","timestamp":1772203421230,"version":"3.50.1"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0199450","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T13:32:40Z","timestamp":1530019960000},"page":"e0199450","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting vaccinations for the licensed dengue vaccine: Considerations for serosurvey design"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-9716","authenticated-orcid":true,"given":"Natsuko","family":"Imai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil M.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"ref1","first-page":"1","article-title":"The global burden of dengue: an analysis from the Global Burden of Disease Study 2013","volume":"3099","author":"JD Stanaway","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e3306","DOI":"10.1371\/journal.pntd.0003306","article-title":"Approaches to Refining Estimates of Global Burden and Economics of Dengue","volume":"8","author":"DS Shepard","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"S Bhatt","year":"2013","journal-title":"Nature"},{"key":"ref4","unstructured":"Dengue Vaccine Initiative. Dengue Vaccine Initiative Statement on SAGE Dengue Vaccine Recommendations GENEVA [Internet]. 2016 [cited 29 Jun 2016]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.denguevaccines.org\/sites\/default\/files\/DVIStatement\u2014SAGERecommendationsDengueVaccinesApril2016_0.pdf\" xlink:type=\"simple\">http:\/\/www.denguevaccines.org\/sites\/default\/files\/DVIStatement\u2014SAGERecommendationsDengueVaccinesApril2016_0.pdf<\/ext-link>"},{"key":"ref5","unstructured":"Sanofi Pasteur. Sanofi Pasteur Dengue Vaccine Approved in Costa Rica. In: sanofipasteur.ca [Internet]. 2016 [cited 5 Sep 2016]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.sanofipasteur.ca\/node\/49001\" xlink:type=\"simple\">http:\/\/www.sanofipasteur.ca\/node\/49001<\/ext-link>"},{"key":"ref6","unstructured":"Dengue Vaccine Initiative. Statement by the Dengue Vaccine Initiative on Mexico\u2019s Regulatory Approval of Sanofi Pasteur\u2019s Dengue Vaccine, Dengvaxia\u00ae [Internet]. 2015 [cited 5 Jan 2016] pp. 1\u20135. 10.1007\/s13398-014-0173-7.2"},{"key":"ref7","unstructured":"Dengue Vaccine Initiative. Statement by the Dengue Vaccine Initiative on the Philippines Regulatory Approval of Sanofi Pasteur\u2019s Dengue Vaccine, Dengvaxia\u00ae [Internet]. 2015 [cited 5 Jan 2016] pp. 1\u20135. 10.1007\/s13398-014-0173-7.2"},{"key":"ref8","first-page":"1","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"6736","author":"MR Capeding","year":"2014","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America","volume":"372","author":"L Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"ref10","article-title":"Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease","author":"SR Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e0004821","DOI":"10.1371\/journal.pntd.0004821","article-title":"Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials","volume":"10","author":"S Gailhardou","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"ref12","unstructured":"The Strategic Advisory Group of Experts (SAGE). Summary of the April 2016 meeting of the Strategic Advisory Group of Experts on immunization (SAGE). 2016. 10.1017\/CBO9781107415324.004"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.vaccine.2016.02.004","article-title":"Protective and immunological behavior of chimeric yellow fever dengue vaccine","volume":"34","author":"SB Halstead","year":"2016","journal-title":"Vaccine"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1016\/j.vaccine.2016.06.015","article-title":"Answer to the review from Halstead and Russell \u201cProtective and immunological behavior of chimeric yellow fever dengue vaccine\u201d (DOI 10.1016\/j.vaccine.2016.02.004)","volume":"34","author":"SRS Hadinegoro","year":"2016","journal-title":"Vaccine"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1016\/j.vaccine.2016.06.013","article-title":"Response to Hadinegoro et al","volume":"34","author":"SB Halstead","year":"2016","journal-title":"Vaccine"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1016\/j.vaccine.2017.09.089","article-title":"Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age","volume":"35","author":"SB Halstead","year":"2017","journal-title":"Vaccine"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jclinepi.2017.11.019","article-title":"Controversy and debate on dengue vaccine series\u2014paper 1: review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs","volume":"95","author":"AL Dans","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jclinepi.2017.12.024","article-title":"Controversy and debate on dengue vaccine series\u2014paper 2: response to review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs","volume":"95","author":"SRS Hadinegoro","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jclinepi.2017.12.025","article-title":"Controversy and debate on dengue vaccine series\u2014paper 3: final response to review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs","volume":"95","author":"AL Dans","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"ref20","unstructured":"Sanofi Pasteur. Sanofi updates information on dengue vaccine [Internet]. [cited 27 Feb 2018]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/mediaroom.sanofi.com\/sanofi-updates-information-on-dengue-vaccine\/\" xlink:type=\"simple\">http:\/\/mediaroom.sanofi.com\/sanofi-updates-information-on-dengue-vaccine\/<\/ext-link>"},{"key":"ref21","year":"2017"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/01621459.1934.10502684","article-title":"Derivation of rates from summation data by the catalytic curve","volume":"29","author":"H Muench","year":"1934","journal-title":"J Am Stat Assoc"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1017\/S0950268809990781","article-title":"Seventy-five years of estimating the force of infection from current status data","volume":"138","author":"N Hens","year":"2010","journal-title":"Epidemiol Infect"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e0003719","DOI":"10.1371\/journal.pntd.0003719","article-title":"Estimating Dengue Transmission Intensity from Sero-Prevalence Surveys in Multiple Countries","volume":"9","author":"N Imai","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref25"},{"key":"ref26"},{"key":"ref27","article-title":"Internet]","year":"2016","journal-title":"Internet]"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2017. 10.1007\/978-3-540-74686-7","DOI":"10.1007\/978-3-540-74686-7"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/bmj.327.7417.716","article-title":"Understanding sensitivity and specificity with the right side of the brain","volume":"327","author":"T-W Loong","year":"2003","journal-title":"BMJ"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3109\/08958378.2014.955932","article-title":"Screening tests: a review with examples","volume":"26","author":"LD Maxim","year":"2014","journal-title":"Inhal Toxicol. Taylor & Francis"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"World Health Organization. Dengue vaccine: WHO position paper\u2014July 2016. World Health Organiszation_ Weekly epidemiological report. 2016. 10.1371\/jour","DOI":"10.1016\/j.vaccine.2016.10.070"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0035-9203(87)90456-1","article-title":"Serological survey on dengue virus infection in Singapore","volume":"81","author":"KT Goh","year":"1987","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4269\/ajtmh.12-0150","article-title":"High rates of inapparent dengue in older adults in Singapore","volume":"88","author":"G Yap","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.47102\/annals-acadmedsg.V38N8p667","article-title":"Seroepidemiology of dengue virus infection among adults in Singapore","volume":"38","author":"YW Yew","year":"2009","journal-title":"Ann Acad Med Singapore"},{"key":"ref35","unstructured":"Health Sciences Authority Singapore. HSA Approves Dengvaxia Vacine [Internet]. 2016 [cited 13 Jun 2017]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hsa.gov.sg\/content\/hsa\/en\/News_Events\/HSA_Updates\/2016\/hsa-approves-dengvaxiavaccine.html\" xlink:type=\"simple\">http:\/\/www.hsa.gov.sg\/content\/hsa\/en\/News_Events\/HSA_Updates\/2016\/hsa-approves-dengvaxiavaccine.html<\/ext-link>"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1371\/journal.pmed.0050205","article-title":"Spatial and Temporal Clustering of Dengue Virus Transmission in Thai Villages","volume":"5","author":"MP Mammen","year":"2008","journal-title":"PLoS Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1017\/S095026880999046X","article-title":"Geographical heterogeneity of dengue transmission in two villages in southern Vietnam","volume":"138","author":"KTD Thai","year":"2010","journal-title":"Epidemiol Infect"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/aje\/kwt256","article-title":"Revisiting Rayong: Shifting Seroprofiles of Dengue in Thailand and Their Implications for Transmission and Control","volume":"179","author":"I Rodriguez-Barraquer","year":"2013","journal-title":"Am J Epidemiol"},{"key":"ref39","unstructured":"World Health Organization. Informing vaccination programs: a guide to the design and conduct of dengue serosurveys. Geneva; 2017."},{"key":"ref40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/CVI.05717-11","article-title":"Comparison of seven commercial antigen and antibody enzyme-linked immunosorbent assays for detection of acute dengue infection","volume":"19","author":"SD Blacksell","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1128\/CDLI.5.1.7-10.1998","article-title":"Evaluation of a commercial capture enzyme-linked immunosorbent assay for detection of immunoglobulin M and G antibodies produced during dengue infection","volume":"5","author":"CT Sang","year":"1998","journal-title":"Clin Diagn Lab Immunol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0732-8893(99)00150-9","article-title":"Evaluation of three commercially available kits for serological diagnosis of dengue haemorrhagic fever","volume":"36","author":"A Chakravarti","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1073\/pnas.1607931113","article-title":"Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus","volume":"113","author":"L Priyamvada","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1128\/CDLI.11.4.642-650.2004","article-title":"Current advances in dengue diagnosis","volume":"11","author":"PY Shu","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1590\/S0124-00642008000200010","article-title":"Dengue-yellow fever sera cross-reactivity; challenges for diagnosis","volume":"10","author":"N Houghton-Trivino","year":"2008","journal-title":"Rev Salud Publica"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"e0005269","DOI":"10.1371\/journal.pntd.0005269","article-title":"Update on Zika Diagnostic Tests and WHO?s Related Activities","volume":"11","author":"A Chua","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1017\/S0022172400062859","article-title":"The estimation of age-related rates of infection from case notifications and serological data","volume":"95","author":"BT Grenfell","year":"1985","journal-title":"J Hyg"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2307\/2347126","article-title":"A catalytic model of infection for measles","author":"DA Griffiths","year":"1974","journal-title":"Appl Stat"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/sim.4780090811","article-title":"Modelling forces of infection for measles, mumps and rubella","volume":"9","author":"CP Farrington","year":"1990","journal-title":"Stat Med"},{"key":"ref50","article-title":"Time-varying, serotype-specific force of infection of dengue virus","author":"RC Reiner","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"e935","DOI":"10.1371\/journal.pntd.0000935","article-title":"From re-emergence to hyperendemicity: the natural history of the dengue epidemic in Brazil","volume":"5","author":"I Rodriguez-Barraquer","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"e0003906","DOI":"10.1371\/journal.pntd.0003906","article-title":"The Hidden Burden of Dengue and Chikungunya in Chennai, India","volume":"9","author":"I Rodr\u00edguez-Barraquer","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"e0004833","DOI":"10.1371\/journal.pntd.0004833","article-title":"Estimating Dengue Transmission Intensity from Case-Notification Data from Multiple Countries","volume":"10","author":"N Imai","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.actatropica.2009.10.021","article-title":"Seroprevalence and risk factors for dengue infection in socio-economically distinct areas of Recife, Brazil","volume":"113","author":"C Braga","year":"2010","journal-title":"Acta Trop"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda\u2019s tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"X S\u00e1ez-Llorens","year":"2017","journal-title":"Lancet Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0199450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T06:40:09Z","timestamp":1693723209000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0199450"}},"subtitle":[],"editor":[{"given":"Ray","family":"Borrow","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0199450","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/171140","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]}}}